Trial Profile
Phase II trial of ibudilast [MN 166] in patients with relapsing-remitting multiple sclerosis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2010
Price :
$35
*
At a glance
- Drugs Ibudilast (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 03 Mar 2010 Results published in Neurology.
- 18 Sep 2008 Results will be presented at the 2008 World Congress on Treatment and Research in Multiple Sclerosis according to a MediciNova media release.
- 27 Apr 2007 Primary endpoint 'Number of multiple sclerosis lesions at 1 year' has not been met.